Introduction
============

One of the central features of schizophrenia is cognitive impairment ([@B6]; [@B50]), which may include both higher-order functions, such as working memory, and essential sensory functions like auditory function ([@B20]; [@B23]). Mismatch negativity (MMN) is a negative component of the auditory event-related potential (ERP), which may be indicative of the neural mechanisms of cognitive dysfunction that occur in patients with schizophrenia ([@B34]; [@B13], [@B23]). In addition, MMN is a key component of auditory and visual change detection in the environment ([@B40]). MMN deficits have been identified in patients with first-episode schizophrenia (FES; [@B15]; [@B33]), patients with chronic schizophrenia (CS; [@B43]; [@B31]), and ultra-high risk individuals (UHR; [@B17]; [@B39]). In return, MMN has been proposed as a biomarker for the early detection of patients with schizophrenia.

Auditory MMN is typically induced by a response to the auditory oddball paradigm in which repeating standards are interrupted by rare deviant stimuli, which could differ from the standards for multiple characteristics ([@B35]). MMN deficits have been widely investigated in relation to frequency and duration MMN deviants in patients with schizophrenia. However, the relative degree of these deficits remains to be elucidated ([@B1]). Previous studies ([@B43]; [@B31]) found that frequency MMN deficits were common in CS, yet these deficits were not detected in FES. However, duration MMN deficits have been detected in both FES and CS. For this reason, frequency MMN may be an unreliable biomarker for diagnosing patients with schizophrenia during the early stages of this disease, especially when compared with duration MMN ([@B12]).

Despite providing comprehensive information at a physiological level, ERP analyses of MMN offer limited regional details. In contrast to ERP analysis, neuro-oscillatory (event-related spectral perturbation, ERSP) approaches can provide information about underlying ERP disturbances at the circuit and molecular levels simultaneously ([@B23]). Previously, auditory MMN was shown to have primary evoked power within the theta frequency band (4--7 Hz) ([@B10]; [@B18], [@B19]), which is the band closely tied to the function of somatostatin (SST)-expressing ([@B51]) and multipolar bursting-type ([@B2]) GABA interneurons. Some studies have already found that MMN-evoked theta power was impaired in patients with schizophrenia ([@B21]). However, no studies have reported whether there is a difference in evoked theta power deficits between FES and CS.

In order to study the mechanism of MMN impairment in patients with schizophrenia, researchers associate it with clinical symptoms and cognition. When pertaining to the symptom domains in schizophrenia, relations to MMN amplitude deficits have not been detected at this time. Some reports have shown that negative symptoms may be associated with MMN deficits ([@B11]; [@B43]), while other studies have found an association with positive symptoms ([@B45]; [@B8]). However, one meta-analysis failed to detect a relationship between MMN amplitude deficits and symptom domains ([@B49]). Interestingly, antipsychotic drugs do not improve MMN amplitude ([@B48]; [@B37]). D-serine, which functions as an endogenous ligand for the glycine modulatory site of the N-methyl-d-aspartate-type (NMDAR), was previously found to improve MMN amplitude in patients with schizophrenia ([@B25]). More importantly, many studies have also repeatedly demonstrated that NMDAR antagonists (ketamine or MK-801) can reduce MMN ([@B3]), suggesting that MMN generation is associated with NMDAR, but not dopamine receptors.

Recently, researchers have shifted their focus to the correlation between MMN measures and cognition impairment. Some studies reported significant correlations between duration MMN amplitude and cognitive functioning in the domains of verbal fluency ([@B16]), social cognition ([@B52]), and executive functioning ([@B47]). However, a recent study reported significant relationships between MMN amplitude with frequency deviants and cognitive function in the verbal learning domain, but there were no significant relationships with duration deviants ([@B29]). Regarding MMN-evoked theta power, D-serine treatment can also significantly improve theta response ([@B24]). More specifically, the improvement in theta occurs during the preparation interval, which correlates explicitly with an increase in auditory cognitive abilities ([@B25]).

In general, MMN amplitude deficits have been observed in patients with schizophrenia. However, the basis for the difference between frequency and duration MMN deficits in patients with schizophrenia remains to be elucidated. In this study, we hypothesized that the neural mechanisms of duration and frequency MMN deficits are different and deficits occur during various stages of schizophrenia. Therefore, we collected frequency and duration MMN amplitude data from FES and CS to verify our hypothesis. Meanwhile, we used ERSP approaches to acquire the evoked power to the MMN standard stimulus. To the best of our knowledge, this is the first study to concurrently assess the electrophysiological indices of evoked power in both FES and CS. We hypothesized that the evoked power deficits in CS are worse than the FES, similar to the MMN amplitude. Lastly, we analyzed the relationship between MMN measures (amplitude and evoked theta power) and clinical symptoms, sociodemographic measures and cognition impairments to further explore the neural mechanism.

Materials and Methods {#s1}
=====================

Participants
------------

Eighty-five patients with schizophrenia were recruited from Beijing Anding Hospital, Capital Medical University. For inclusion in this study, the diagnoses were validated with the Structured Clinical Interview for DSM-IV (SCID). FES was classified as appearing within three years of entry into this study, while CS appeared more than five years before entry into this study. HC were recruited by advertisement and had no DSM-IV axis I disorders.

The age range was 18--45 years old, and all participants had IQs ≥ 70. The exclusion criteria for this study included hearing disorders, learning disabilities, neurological impairments, and histories of seizures, head injuries, electroconvulsive therapy, and drug abuse. The Ethics Committee of Beijing Anding Hospital reviewed and approved this study and all subjects provided informed consent prior to inclusion.

Procedures
----------

The auditory stimuli consisted of a sequence of binaural tones (825 trials) that were presented in random order with a stimulus onset asynchrony of 500--550 ms. Standard tones (675 trials, 82%) were 1000 Hz, 75 dB, and 50 ms in duration. Deviant tones included frequency and duration deviants. Frequency deviants (75 trials, 9%) were 1500 Hz, 75 dB, and 50 ms in duration. Duration deviants (75 trials, 9%) were 1000 Hz, 75 dB, and 100 ms in duration. At the beginning of the paradigm, the first 15 stimuli were used as the standard.

Electroencephalogram (EEG) Data Acquisition and Processing
----------------------------------------------------------

Electroencephalogram (EEG) data were collected from all of the subjects using the 128-channel electrode system (Electrical Geodesics, Inc., Eugene, OR, United States) with ground procedures and standard reference. The impedance of the signal was adjusted to ≥50 KΩ with a sampling rate of 1000 Hz. During the experiment, the subjects were seated comfortably in a light and sound-attenuated room to remove potentially interfering variables from the study. The test consisted of three sections with a 60 s break between each section.

For the ERP analyses, the EEG data were analyzed and processed using EEGLAB 14.1.1b^[1](#fn01){ref-type="fn"}^, which is a neural electrophysiological analysis tool based on MATLAB (MathWorks, Natick, MA, United States). The EEG data were processed using a 0.1--40 Hz bandpass filter (finite impulse response filter). The 50 Hz power frequency noise was subject to notch processing. The reference electrode was changed to a global brain average reference. Artifacts due to eye movement were excluded by independent component analysis (ICA; [@B32]). The EEG was segmented from 100 ms prior to initiation to 500 ms after the stimulus onset. MMN waveforms were collected by subtracting the standard from the deviant stimulus at the frontal midline (Fz) electrode ([Figure 1A,B](#F1){ref-type="fig"}).

![**(A)** Event-related potential (ERP) waveforms to frequency deviant stimuli. **(B)** ERP waveforms to duration deviant stimuli. **(C1--C3)** Correlations between frequency MMN and MCCB verbal learning showing a significant relationship with the healthy control group and first-episode schizophrenia group. **(D1--D3)** Correlations between frequency MMN and the mean MCCB combined score showing a significant association between the healthy control group and the first-episode schizophrenia group.](fnbeh-13-00037-g001){#F1}

For evoked (average) power analyses, ERP waves were transformed with the short-time Fourier transformation (STFT) method using MATLAB (MathWorks, Natick, MA, United States). Continuous wavelet transformation was carried out for the segmented EEG signal time. The EEG time range was from 100 ms before initiation to 500 ms after the stimulus onset, which was relative to the stimulus presentation time. The frequency range of the wavelet transformation was 1--20 Hz. Additionally, the temporal values of power corresponding to each frequency point were averaged across the trials, and thus EEG power time-frequency distribution was attained channel by channel. We extracted the maximum power values between 1--20 Hz and 100--250 ms of each subject for statistical analysis, and the range of the maximum value is within the theta frequency band of 4--7 Hz. We considered the theta frequency band to be the primary active frequency band of the nerve oscillation to the standard stimulus ([Figure 2A1--A3](#F2){ref-type="fig"}).

![**(A1--A3)** Evoked power plots for standard stimuli. Box indicates the integration window for the theta band response (4--7 Hz, 150--250 ms). **(B1--B3)** Correlations between evoked theta power and MCCB working memory showing a significant relationship between all three groups.](fnbeh-13-00037-g002){#F2}

Clinical, Intelligence Quotient and Neuropsychological Assessment
-----------------------------------------------------------------

The clinical symptoms of each patient were evaluated with the Positive and Negative Symptom Scale (PANSS, Chinese version), which was described previously ([@B14]). The Chinese intelligence quotient (IQ) test tool is a revised short form of the Wechsler adult intelligence scale-revised, and the four included subsets for this evaluation were information, similarities, picture completion, and block design ([@B38]). The MATRICS consensus cognitive battery (MCCB, Chinese version) was used to evaluated cognitive deficits in patients with schizophrenia and healthy controls ([@B44]).

Statistical Analysis
--------------------

Data analyses were performed using SPSS 20.0 (IBM, Chicago, IL, United States). Continuous variables were checked using one-way analysis of variance (ANOVA) and classified variables using the Chi-square test. Analysis of covariance was used to adjust for confounding effects of cognition among groups. A two-factorial mixed ANOVA with deviant type as within-subject factor and the between-subject factor groups was carried out. Associations between MMN values and the scores from the MCCB tasks or the PANSS scale were analyzed using Pearson's correlation analysis. The statistical test used a significance level of *p* \< 0.05. *P*-values were corrected using Bonferroni adjustment (B-adjusted). Cohen's effect size was used to analyze the differences between the means of each group. Measurement of the effect size was based on the Cohen coefficient ([@B5]) with *d* \< 0.2 as a negligible effect size, 0.2--0.5 as a small effect size, 0.5--0.8 as a medium effect size, and *d* \> 0.8 as a large effect size.

Results
=======

Demographics and Clinical Characteristics of Patients
-----------------------------------------------------

Three FES and two CS were excluded from this study due to low-quality EEG data. In total, 40 FES, 40 CS, and 40 HC were enrolled in the study. The demographic characteristics and clinical data for the remaining participants are summarized in [Table 1](#T1){ref-type="table"}. There were no significant differences in age (*df* = 2,117, *F* = 2.742, *p* = 0.069), gender (χ^2^ = 1.364, *p* = 0.506), or education (*df* = 2, 117, *F* = 1.476, *p* = 0.233) among the three groups.

###### 

Demographic and clinical characteristics of patients with first-episode schizophrenia, chronic schizophrenia, and healthy controls.

  Variable                                   Group    Analysis   *post hoc* Tests *p*, Bonferroni-adjusted                                                                                  
  ------------------------------------------ -------- ---------- ------------------------------------------- ------- ------- -------- -------- -------- --------- ------------ ------------ -----------
  Age (years)                                25.63    6.21       28.50                                       5.34    26.33   5.60     2, 117   2.742    0.069     0.08         1.000        0.276
  Education (years)                          13.40    2.87       13.88                                       2.62    14.48   2.91     2, 117   1.476    0.233     1.000        0.267        1.000
  IQ                                         101.48   12.403     105.58                                      9.732   114.1   13.345   2, 117   11.667   \<0.001   0.381        \<0.001      0.005
  Age at illness onset (years)               24.48    6.27       21.35                                       4.84    --      --       1, 78    6.231    0.015     --           --           --
  Duration of illness (months)               14.15    9.24       90.03                                       37.71   --      --       1, 78    152.8    \<0.001   --           --           --
  **Positive and Negative Syndrome Scale**                                                                                                                                                  
  Positive scale score                       20.98    5.55       21.60                                       3.95    --      --       1, 78    0.337    0.563     --           --           --
  Negative scale score                       20.35    5.90       19.65                                       4.80    --      --       1, 78    0.339    0.562     --           --           --
  General psychopathology score              40.1     6.11       42.18                                       5.57    --      --       1,78     2.524    0.116     --           --           --
  PANSS score                                81.43    12.33      83.43                                       10.25   --      --       1,78     0.622    0.433     --           --           --
                                             N        \%         N                                           \%      N       \%       df       χ2       *p*       FES vs. CS   FES vs. HC   CS vs. HC
  Sex (Male, %)                              28       70         23                                          57.5    25      62.5     2        1.364    0.506     0.245        0.478        0.648
  **Antipsychotic treatment**                                                                                                                                                               
  None                                       24       60         4                                           10      --      --       --       --       --        --           --           --
  First-generation antipsychotic             0        0          0                                           0       --      --       --       --       --        --           --           --
  Second-generation antipsychotic            16       40         36                                          90      --      --       --       --       --        --           --           --

∗

FES = First-episode Schizophrenia; CS = Chronic Schizophrenia; HC = Healthy Controls; IQ = intelligence quotient; -- = Not Available

.

As expected, the HC had a higher IQ (*df* = 2, 117, *F* = 11.667, *p* \< 0.001) and better MCCB task performance than FES and CS. The MCCB domain scores and statistical analyses are shown in [Table 2](#T2){ref-type="table"}. In analyzing covariance for IQ, the differences among groups remained significant for all the MCCB domains (*df* = 2, 117, *F*~speed\ of\ processing~ = 27.548, *p* \< 0.001; *F*~attention/vigilance~ = 37.489, *p* \< 0.001; *F*~working\ memory~ = 13.318, *p* \< 0.001; *F*~verbal\ learning~ = 7.53, *p* = 0.001; *F*~visual\ learning~ = 3.69, *p* = 0.028; *F*~reasoning\ and\ problemsolving~ = 11.035, *p* \< 0.001, *F*~social\ cognition~ = 3.321, *p* = 0.04; *F*~MCCB\ combine~ = 31.889, *p* \< 0.001).

###### 

MATRICS consensus cognitive battery (MCCB) domain-scores for first-episode schizophrenia, chronic schizophrenia, and healthy control groups.

  Variable                        Group   Analysis   *post hoc* Tests *p*, Bonferroni-adjusted                                                                        
  ------------------------------- ------- ---------- ------------------------------------------- ------- ------- ------ -------- -------- --------- ------- --------- ----------
  Speed of processing             35.88   7.65       34.88                                       8.09    48.18   6.13   2, 117   40.778   \<0.001   1.000   \<0.001   \<0.001
  Attention/Vigilance             29.58   10.64      24.7                                        12.23   46.4    7.44   2, 117   48.907   \<0.001   0.109   \<0.001   \<0.001
  Working memory                  39.25   8.23       37.45                                       7.96    48.1    6.95   2, 117   21.736   \<0.001   0.900   \<0.001   \<0.001
  Verbal learning                 37.78   7.28       39.93                                       9.49    48.4    9.17   2, 117   16.67    \<0.001   0.814   \<0.001   \<0.001
  Visual learning                 41.83   11.32      39.2                                        11.68   48.5    11.5   2, 117   7.738    0.001     0.851   0.021     0.001
  Reasoning and problem solving   33.28   10.57      33.53                                       8.59    45.6    9.87   2, 117   21.054   \<0.001   1.000   \<0.001   \< 0.001
  Social cognition                29.95   9.81       29.8                                        11.31   37.45   9.57   2, 117   7.223    0.001     1.000   0.004     0.004
  MCCB combine                    35.6    6.41       34.4                                        6.53    46.1    5.29   2, 117   44.524   \<0.001   1.000   \<0.001   \< 0.001

∗

FES = First-episode Schizophrenia; CS = Chronic Schizophrenia; HC = Healthy Controls

.

Mismatch Negativity to Different Deviants
-----------------------------------------

Results showing the differences in frequency MMN, duration MMN, and standard ERSP between the three groups are shown in [Table 3](#T3){ref-type="table"}. More specifically, these findings describe the relative magnitude of MMN deficits between the groups. As predicted, there was a significant difference among the three groups in both frequency MMN (*df* = 2, 117, *F* = 30.968, *p* \< 0.001) and duration MMN (*df* = 2, 117, *F* = 23.962, *p* \< 0.001).

###### 

Mismatch negativity amplitudes and event-related spectral perturbation indexes.

  Variable             Group     Analysis   *post hoc* Tests *p*, Bonferroni-adjusted   Cohen's d                                                                                       
  -------------------- --------- ---------- ------------------------------------------- ----------- --------- -------- -------- -------- --------- ---------- ------- ---------- ------ ------
  Frequency MMN (μV)   -0.8557   0.2295     -0.57                                       0.2102      -0.94     0.221    2, 117   30.968   \<0.001   \<0.001    0.269   \< 0.001   0.37   1.72
  Duration MMN (μV)    -1.6366   0.4801     -0.9146                                     0.3035      -1.8893   0.5654   2, 117   47.802   \<0.001   \< 0.001   0.048   \< 0.001   0.48   2.15
  Standard ERSP        0.0411    0.0249     0.0366                                      0.0276      0.0846    0.0793   2, 117   10.98    \<0.001   1.000      0.001   \< 0.001   0.74   0.81

∗

FES = First-episode Schizophrenia; CS = Chronic Schizophrenia; HC = Healthy Controls; MMN = Mismatch Negativity

.

When compared to HC, there was no significant difference with FES in terms of frequency MMN (*p* = 0.269, Bonferroni-adjusted), and the Cohen's effect size was small (*d* = 0.37). However, the difference was significant (*p* \< 0.001, Bonferroni-adjusted) and the Cohen's effect size was large (*d* = 1.72) when comparing CS with HC. Meanwhile, in terms of duration MMN, both FES (*p* = 0.048, Bonferroni-adjusted) and CS (*p* \< 0.001, Bonferroni-adjusted) showed significant differences when compared with HC. The Cohen's effect size for FES and CS were approximately medium (*d* = 0.48) and large (*d* = 2.15), respectively. When the two patient groups were compared, there was a significant main effect for both frequency MMN (*p~F~* \< 0.001, Bonferroni-adjusted) and duration MMN (*p~d~* \< 0.001, Bonferroni-adjusted).

The results of two-factorial mixed ANOVA with the deviant type (frequency and duration) as within-subject and between-subject factor groups (FES and CS) showed that the effects within subjects were significant (*F* = 167.023, *p* \< 0.001), and the effects between subjects were also significant (*F* = 75.835, *p* \< 0.001). The interaction effects with MMN type (frequency vs. Duration) ^∗^ Group were also significant (*F* = 25.112, *p* \< 0.001).

The relationship between MMN amplitude and several variables, including sociodemographic variables, MCCB tests, and PANSS scale scores, are described in [Tables 4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}. As we expected, no significant correlations were found between MMN amplitude and sociodemographic variables or MMN amplitude and PANSS scale scores. In terms of the MCCB tests, both FES (*r* = -0.327, *p* = 0.039, [Figure 1D2](#F1){ref-type="fig"}) and HC frequency MMN (*r* = -0.438, *p* = 0.005, [Figure 1D1](#F1){ref-type="fig"}) were strongly correlated with overall cognitive functioning, as assessed by the combined MCCB scores. However, CS frequency MMN was not associated with overall cognitive functioning. Of the three groups, only the duration MMN (*r* = -0.341, *p* = 0.032) of the healthy control group was found to correlate with overall cognitive function. Among the individual MCCB items, the correlation between frequency MMN and verbal learning was detected in FES (*r* = -0.328, *p* = 0.039, [Figure 1C2](#F1){ref-type="fig"}) and HC (*r* = -0.583, *p* \< 0.001, [Figure 1C1](#F1){ref-type="fig"}), yet it was not observed in CS. In contrast, HC showed weak correlations between duration MMN and speed of processing (*r* = -0.326, *p* = 0.04), as well as duration MMN and social cognition (*r* = -0.335, *p* = 0.034). However, when using the Bonferroni correction, only the correlation between frequency MMN and MCCB verbal learning in HC was statistically significant, suggesting that the respective correlations are only significant on a descriptive level.

###### 

Correlation between mismatch negativity measures with age, age at illness onset, duration of illness, and PANSS scores.

  Variable                        FES (*n* = 40) (r)   CS (*n* = 40) (r)                              
  ------------------------------- -------------------- ------------------- -------- -------- -------- -----------
  Positive scale score            0.026                -0.036              -0.176   -0.149   0.051    -0.142
  Negative scale score            0.167                0.140               0.002    0.198    0.179    -0.395^∗^
  General psychopathology score   -0.074               -1.113              0.025    0.159    0.118    -0.144
  PANSS score                     0.055                -0.005              -0.053   0.122    0.168    -0.318^∗^
  Age (years)                     0.022                -0.057              0.228    0.09     -0.185   0.176
  Age at illness onset (years)    -0.007               -0.062              0.256    0.202    -0.140   0.193
  Duration of illness (months)    0.215                0.095               -0.236   -0.13    -0.138   0.002

∗

FES = First-episode Schizophrenia; CS = Chronic Schizophrenia; MMN = Mismatch Negativity; ERSP = event-related spectral perturbation; PANSS = Positive and Negative Symptom Scale;

∗

p \< 0.05

.

###### 

Correlation between mismatch negativity measures and the MATRICS consensus cognitive battery domain.

  Variable                        FES (*n* = 40) (r)   CS (*n* = 40) (r)   HC (*n* = 40) (r)                                                          
  ------------------------------- -------------------- ------------------- ------------------- -------- -------- ----------- ------------ ----------- ----------
  Speed of processing             -0.276               -1.115              0.162               -0.126   -0.064   0.202       -0.286       -0.326^∗^   0.158
  Attention/Vigilance             -0.301               -0.066              0.191               -0.179   0.072    -0.257      -0.136       -0.036      0.091
  Working memory                  -0.146               0.01                0.347^∗^            -0.095   -0.091   0.408^∗∗^   -0.241       -0.13       0.361^∗^
  Verbal learning                 -0.328^∗^            -0.008              -0.193              -0.219   -0.084   -0.052      -0.583^∗∗^   -0.096      0.143
  Visual learning                 -0.192               -0.105              0.084               -0.292   -0.156   0.16        -0.059       -0.218      0.2
  Reasoning and problem solving   -0.227               -0.04               0.16                0.087    -0.216   0.309       -0.352^∗^    -0.285      0.139
  Social cognition                -0.089               -0.168              0.24                -0.026   0.012    0.085       -0.214       -0.335^∗^   0.14
  MCCB combine                    -0.327^∗^            -0.113              0.21                -0.205   -0.118   0.158       -0.438^∗∗^   -0.341^∗^   0.271

∗

FES = First-episode Schizophrenia; CS = Chronic Schizophrenia; HC = Healthy Controls; MMN = Mismatch Negativity; MCCB = the MATRICS consensus cognitive battery; ERSP = event-related spectral perturbation;

∗

p

\< 0.05;

∗∗

p

\< 0.01

.

Evoked Theta Power to the Standard Stimulus
-------------------------------------------

The differences in evoked theta power among the three groups may be found in [Table 3](#T3){ref-type="table"}. There was also a significant difference among the three groups (*df* = 2, 117, *F* = 10.98, *p* \< 0.001). Both patient groups showed significant reductions in the evoked theta power when compared with the HC (*p~*FES*~* = 0.001, *p~*CS*~* \< 0.001, Bonferroni-adjusted), yet there was no significant difference between the two patient groups (*p* = 1.000, Bonferroni-adjusted). The Cohen's effect size for FES was medium (*d* = 0.74), while the Cohen's effect size for CS was large (*d* = 0.81).

As shown in [Table 5](#T5){ref-type="table"}, in terms of MCCB domain correlations, all three groups measures were significantly correlated with working memory (*r*~HC~ = 0.361, *p*~HC~ = 0.022, [Figure 2B1](#F2){ref-type="fig"}; *r*~FES~ = 0.347, *p*~FES~ = 0.028, [Figure 2B2](#F2){ref-type="fig"}; *r*~CS~ = 0.408, *p*~CS~ = 0.009, [Figure 2B3](#F2){ref-type="fig"}). However, there were no statistically significant findings on the correlation analysis using the Bonferroni correction, which indicated that the respective correlations were only significant on a descriptive level.

Discussion
==========

Mismatch negativity generation deficits have been recognized as one of the best potential biomarkers of cognitive impairment in patients with schizophrenia ([@B36]). While MMN deficits have been detected in several deviant types, the most extensively studied are those of duration and frequency, as both of these have been found to be significantly impaired in patients with schizophrenia ([@B9]). Some researchers have found differential impairments in frequency and duration MMN and suggested that deficits in duration deviants may be more sensitive indices of MMN reduction during the early stages of schizophrenia ([@B46]). In our study, compared to HC, frequency MMN was only impaired in CS, but duration MMN was impaired in both FES and CS. Therefore, our results confirmed this viewpoint. A recent meta-analysis ([@B12]), which compared the results from several studies that measured MMN reduction in patients with first-episode schizophrenia-spectrum, showed a negligible effect size of 0.04 SD for MMN to frequency deviants and a small-to-medium effect size of 0.47 SD for duration deviants. In the individuals at ultra-high risk (UHR; [@B27]), duration MMN was significantly smaller when compared with the HC. However, frequency MMN did not differ between the UHR individuals and HC. These similar findings suggest that duration MMN is a better biomarker for the early identification of the patients with schizophrenia than frequency MMN.

Both frequency and duration MMN deficits in CS were more severe when compared with FES, and the within- and between-subject effects were also significant, suggesting that MMN amplitude deficits may correlate with the progression of the patients with schizophrenia. However, MMN deficits were not significantly associated with disease duration in either of the deviant types between the two patient groups, which is in agreement with a recent meta-analysis ([@B7]). One conceivable explanation is that MMN impairment worsens within the first 1 to 2 years after the diagnosis, but stabilizes after this critical period. Previously, Salisbury et al. ([@B41]) discovered a progressive course of MMN impairment during the initial 18 months of the disease. Nevertheless, our study did not find that MMN deficits in FES (mean duration of illness was 14.15 months) have any significant relationship with the length of illness. Another possible explanation to this controversy is that MMN deficits may be related to the age of the patients ([@B46]), yet several studies ([@B29],[@B30]), including the current investigation, have shown no correlation between MMN and patient age. Additionally, we did not detect this association with age at illness onset.

While we showed that differential deficits in frequency and duration MMN between FES and CS remain controversial, the correlation study with MCCB showed that the neural processing mechanism of duration and frequency MMN might be different. The results of our study showed that frequency MMN deficits were related to MCCB verbal learning (T-score) in the HC and FES, yet duration MMN deficits were not significantly associated with any cognitive domains in MCCB from either group. This may suggest that frequency MMN is a potential marker that can be correlated with auditory functioning early on in patients with schizophrenia. Similarly, previous researchers found that frequency MMN is intact in FES ([@B12]), especially in patients with high premorbid functioning ([@B42]). However, even in these patients, declines in frequency MMN occur over the first few years of the disease in parallel with structural changes in the auditory cortex ([@B22]; [@B26]). In summary, duration MMN may be related to premorbid aspects of patients with schizophrenia, while frequency MMN may be relevant to the decline in cognitive functioning that occurs during the early stages of patients with schizophrenia ([@B29]).

Another important discovery of our study is that deficits in theta power response to standard stimuli were significantly impaired in both groups. Similarly, Lee et al. found that lower frequency oscillations were sparked, especially by the MMN, that may be mapped to the theta frequency range, and that these oscillations are impaired in patients with schizophrenia ([@B28], [@B30]). However, their recent study ([@B29]) also found that alpha power was significantly impaired in patients with schizophrenia. In return, low-range alpha and theta oscillatory frequencies may contribute to MMN, as they are all impaired in patients with schizophrenia. Our study also found that theta power responses to standard stimuli deficits could not distinguish between FES and CS. More interestingly, theta power response was significantly correlated with MCCB working memory in all three groups. A recent review proposed that theta frequency generation may be tied to the impaired interplay between the cortical pyramidal neurons and local circuit SST-type GABAergic interneurons ([@B21]). In addition, another study suggested that working memory may be correlated with GABA levels in patients with schizophrenia ([@B4]), which may indicate that theta power response to standard stimuli is a marker of auditory working memory in patients with schizophrenia.

Conclusion
==========

In conclusion, we show the differential MMN measures of deficits between FES and CS. Frequency MMN was not impaired in FES when compared with HC, and it was correlated with MCCB verbal learning. Duration MMN and theta-evoked power were impaired in both patient groups. In addition, duration MMN deficits were not correlated with any MCCB domain, yet theta-evoked power deficits were correlated with MCCB working memory in all three groups. These results suggest that the mechanisms of frequency and duration mismatch negativity and theta power deficits in FES and CS are different, and that the processes may occur during various stages of the disease. Duration MMN may be a more sensitive biomarker during the early stages of patients with schizophrenia, while frequency MMN and theta power response to standard stimuli may be linked to a reduction in the cognitive functioning of patients with schizophrenia.

Limitations
===========

There are two primary methodological limitation for the current study that should be considered. First, some of the FES patients were already receiving antipsychotic therapy, so we were unable to completely rule out the potential effects of concurrent therapeutic intervention. Secondly, the age at illness onset of CS is generally earlier than that of FES. As we wanted to ensure that age was matched between the subjects, there may be some heterogeneity between the subjects.
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